Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P27539
UPID:
GDF1_HUMAN
Alternative names:
-
Alternative UPACC:
P27539; O43344
Background:
Embryonic growth/differentiation factor 1 (EGDF1), encoded by the gene with accession number P27539, plays a pivotal role in cell differentiation during embryonic development. This protein's involvement in key developmental processes underscores its importance in the formation and maturation of various tissues and organs.
Therapeutic significance:
EGDF1 is linked to several congenital heart defects, including Conotruncal heart malformations, multiple types of Congenital heart defects, Tetralogy of Fallot, and Right atrial isomerism. These associations highlight the protein's critical role in heart development and present it as a potential target for therapeutic interventions aimed at preventing or treating these heart conditions.